---
document_datetime: 2025-12-19 12:46:32
document_pages: 8
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/minjuvi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: minjuvi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.5349273
conversion_datetime: 2025-12-28 03:51:54.629445
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## MINJUVI

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IA /  | This was an application for a group of | 12/12/2025                          | N/A                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000317412                     | variations. B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted   |            |     |          |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------|
| Variation type IA / EMA/VR/0000309782 | A.5 Change in the name and/or address of a manufacturer/importer of the finished product (including batch release or quality control testing sites) - A.5.b The activities for which the manufacturer/importer is responsible do not include batch release - Accepted                                                                                                                                                                                                   | 27/11/2025 | N/A |          |
| Variation type II / EMA/VR/0000269625 | This was an application for a group of variations. B.I.d.1.a Re-test period/storage period - B.I.d.1.a.4 Extension or introduction of a re- test period/storage period supported by real time data - Accepted                                                                                                                                                                                                                                                           | 30/10/2025 |     | Annex II |

<div style=\"page-break-after: always\"></div>

| B.I.d.1 Change in the re-test period/storage period or storage conditions of the active substance where no Ph. Eur. Certificate of Suitability covering the retest period is part of the approved dossier - B.I.d.1.c Change to an approved stability protocol - Accepted  B.I.b.2 Change in test procedure for active  substance or starting  material/reagent/intermediate used in the  manufacturing process of the active  substance - B.I.b.2.a Minor changes to an  approved test procedure - Accepted  B.I.b.2 Change in test procedure for active  substance or starting  material/reagent/intermediate used in the  manufacturing process of the active  substance - B.I.b.2.a Minor changes to an  approved test procedure - Accepted  B.I.b.2 Change in test procedure for active  substance or starting  material/reagent/intermediate used in the  manufacturing process of the active  substance - B.I.b.2.a Minor changes to an  approved test procedure - Accepted  B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| substance - B.I.b.2.a Minor changes to an  approved test procedure - Accepted  B.I.b.2 Change in test procedure for active  substance or starting  material/reagent/intermediate used in the  manufacturing process of the active  substance - B.I.b.2.a Minor changes to an  approved test procedure - Accepted  B.I.b.2 Change in test procedure for active  substance or starting  material/reagent/intermediate used in the  manufacturing process of the active  substance - B.I.b.2.a Minor changes to an  approved test procedure - Accepted  B.I.b.2 Change in test procedure for active  substance or starting  material/reagent/intermediate used in the  manufacturing process of the active  substance - B.I.b.2.a Minor changes to an  approved test procedure - Accepted  B.II.b.4 Change in the batch size (including  batch size ranges) of the finished product -  B.II.b.4.c The change requires assessment  of the comparability of a  biological/immunological medicinal product  or the change in batch size requires a new  bioequivalence study - Accepted   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                                       | B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.e The change relates to a biological active substance or a starting material/reagent/intermediate used in the manufacture of a biological/immunological product - Accepted   |            |            |          |                                                                                                                                                                                                                                               |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000302636 | C.I.11 Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.z Change in due date for category 1, 2 or 3 studies in the RMP and/or Annex II - Accepted C.I.11.z - to update Annex II.E of the Product Information and the RMP to change the due date for the Specific Obligation MOR208C310 (frontMIND), from 'December 2025' to 'December 2026'.                                                                                       | 24/10/2025 |            | Annex II |                                                                                                                                                                                                                                               |
| Renewal - 1 year / EMA/R/0000256675   | - Renewal - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 24/07/2025 | 17/09/2025 | Annex II | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal |

<div style=\"page-break-after: always\"></div>

|                                       |                                                                                                                                                                                                                                                                                                                                                                                                         |            |     | product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for MINJUVI, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion. The SOB relating to the B-MIND study is fulfilled and therefore deleted from the SmPC. In addition, the SOB relating to the frontMIND study has been amended and is included in its updated form in the SmPC: 'In order to confirm the efficacy and to re-confirm the safety profile of tafasitamab in combination with lenalidomide the applicant should submit the results of a phase 3, multicentre, randomized, double- blind, placebo-controlled trial comparing tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high- intermediate and high-risk patients with newly-   |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000261395 | This was an application for a group of variations. B.II.d.1 Change in the specification parameters and/or limits of the finished product - B.II.d.1.a Tightening of specification limits - Accepted B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate reagent used in the manufacturing process of the active substance - B.I.b.1.b | 03/04/2025 | N/A |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

|                     | Tightening of specification limits - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |            |     |                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------|
| Variation type IB / | This was an application for a group of variations. B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.c Other changes to a test procedure (including replacement or addition) for a reagent, which does not have a significant effect on the overall quality of the active substance - Accepted B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.a Minor change in the manufacturing process of the active substance - Accepted B.I.a.4 Change to in-process tests or limits applied during the manufacture of the active substance - B.I.a.4.z Minor change of an | 12/02/2025 | N/A | EMA/VR/0000244988 |

<div style=\"page-break-after: always\"></div>

|                            | - Accepted   |             |
|----------------------------|--------------|-------------|
| PSUR / EMA/PSUR/0000269001 | - -          | Maintenance |